Anti-GP39 Uses, Dosage, Side Effects and more
Anti-GP39 is under investigation in clinical trial NCT03605927 (CD40-L Blockade for Prevention of Acute Graft-versus-host Disease).
| Trade Name | Anti-GP39 |
| Generic | Toralizumab |
| Toralizumab Other Names | Anti-CD 154 human-mouse monoclonal antibody, Anti-CD40L, Anti-GP39, Toralizumab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
